Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005874 · ClinicalTrials.gov registry record · Phase 2
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005874: Completed Phase 2 study, sponsored by Astex Pharmaceuticals.
NCT00005874 is a Phase 2 study that has completed, run by Astex Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005874, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.
Interventions
- DRUG rubitecan
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00005874 record still lists
NCT00005874 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which rubitecan is the first listed.
NCT00005874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005874 about?
NCT00005874 is a clinical study titled "Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally advanced or metastatic soft tissue sarcomas.
What is the current status of trial NCT00005874?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00005874?
The interventions under investigation include: rubitecan (DRUG).
Who is sponsoring clinical trial NCT00005874?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia